{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-047402","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.728264+00:00","generated_at":"2026-05-21T15:37:30.027298+00:00","sec_items":["5.02","5.07"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"AbbVie appoints Thomas Falk (ex-Kimberly-Clark CEO) to board; Gonzalez, Tilton to retire July 1","bullets":["Board expanded to 15; Thomas J. Falk (former Kimberly-Clark CEO) appointed as Class III director and to Audit Committee; deemed independent.","Board to shrink to 13 upon retirement of Richard A. Gonzalez and Glenn F. Tilton effective July 1, 2025.","Compensation Committee raised Robert A. Michael's 2025 annual bonus target to 165% of base salary for Chairman role.","Shareholders ratified EY as auditor and approved say-on-pay; both management and stockholder proposals to eliminate supermajority voting failed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-047402","json":"https://secwatch.observer/filing/0001104659-25-047402.json","markdown":"https://secwatch.observer/filing/0001104659-25-047402.md","text":"https://secwatch.observer/filing/0001104659-25-047402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000110465925047402/0001104659-25-047402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000110465925047402/tm2513856d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T15:37:30.027298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29b1013734","claim":"Richard A. Gonzalez departed as Director at AbbVie Inc..","evidence_excerpt":"The Board also determined that the size of the Board will decrease from fifteen directors to thirteen directors upon the retirement of Richard A. Gonzalez and Glenn F. Tilton from the Board, effective July 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465925047402/0001104659-25-047402-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"654376a209","claim":"Glenn F. Tilton departed as Director at AbbVie Inc..","evidence_excerpt":"The Board also determined that the size of the Board will decrease from fifteen directors to thirteen directors upon the retirement of Richard A. Gonzalez and Glenn F. Tilton from the Board, effective July 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465925047402/0001104659-25-047402-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}